

IMSACON 2008, Dubai, UAE

Annual Conference of International Medical Sciences Academy **IMSACON 2008** will be held on 12-13 October, 2008 at Dubai, UAE.

Dr. Nashi Khan is the organizing Secretary and Dr. Shaheena Asif is the Organizing Chairperson.

Theme : "New Horizons & Controversies in Medical Sciences"

Venue : Dhow Palace, Dubai, UAE

Host : Surgimed Hospital, Lahore, Pakistan.

Visa: Visa is required for Dubai and must be obtained before Travel. Please allow at least 3 months before conference date for application to be processed.

First information brochure can be seen on the IMSA website "www.imsaonline.com". The brochure contains all details about registration fee, registration form, details of Hotel stay etc.

Non fellows accompanying the Fellows of IMSA are welcome to participate. You are requested to register yourself early and participate with your spouse and enjoy hospitality of the hosts.

Registration Fee	Before 31st July 08	After 1st Aug 08 onwards	After 15th Sept. 08
Conference Delegates	\$ 200	\$ 250	\$ 300
Accompanying Person	\$ 150	\$ 200	\$ 250
Trade Delegates	\$ 300	\$ 350	\$ 400
PG Students	\$ 80	\$ 100	\$ 120

HOTELS	Single Room Rates	Double Room Rates
Dhow Palace	\$ 253 + tax	287+ tax
Sea View Hotel	\$ 186 + tax	196+ tax
Admiral Hotel	\$ 114 + tax	129+ tax

Tariff rates are approximate and are subject to revision. The Hotel reserves the right to revise the tariffs and taxes and the secretariat would not be in a position to intervene. The delegates are requested to send requisition for booking their choice of hotel with advance room rent for one day.

Cancellation: Request for cancellation of accommodation must reach the Conference Secretariat latest by 31st July 2008. Cancellation request received after 31st July 2008 will not be entertained.

In case participants intend to present paper in the Scientific Programme of the conference, they may send "Abstract" of the paper to the Chairman Scientific Committee the abstract must be in approximately 300 words in English. Only empirical work based on clinical data may be submitted. The paper must clearly state the objective, methods, results and conclusions. The presentation must have a title, names of all authors and the institution where the work was done. Please mention the name of the author who will present the paper and complete address, email and phone numbers.

Last date for submission of abstract: 30th June 2008. Kindly send the abstract on soft copy through email to Scientific Committee Chair, Prof. Dr. Rukhsana Kausar. Email: rukhsana.saddul@gmail.com

If any one has difficulty in sending registration fee to Pakistan bank from India; they can send registration fee to the following:-

Us Dollars 200 (registration fee only), To Shaheena Asif Choudhary Acc no 3513409044 ABN AMRO Bank Dubai UAE (BIC. ABNAAEAD) Swift BIC ABNAAEADCCC (swift field 57 A) ABN Amro bank, P O Box 2567, Khalid bin waleed street Dubai, UAE. To Further facilitate, the demand draft drawn in favour of Shaheena Asif Choudhary, with full account no, name of bank as given above can also be sent to IMSA World Headquarter at New Delhi which will be passed on to the organizers and confirmation of the registration, will be obtained.

Those who intend to present paper at IMSACON-2008 should send their abstract to **the Scientific Chair Dr. Rukhsana Kausar or Organizing Secretary, Dr. Nashi Khan by e-mail. Their e-mail addresses are given below:-**

1. rukhsana.saddul@gmail.com.
2. nashi.khan@gmail.com

Only those papers will be included in the programme whose registration fee is paid on time.

For details contact:

IMSACON 2008
Conference Secretariat
Dr. Nashi Khan
 Organizing Secretary IMSACON 2008
 Chartered Clinical Psychologist
 PO Box 3222, Gulberg, Lahore, Pakistan
 Mobile: +92 300 8441608
nashi.khan@gmail.com

International Medical Sciences Academy
World Headquarter (IMSA)
Dr. H.K. Chopra
 Secretary General, IMSA WHQ
 Chief Cardiologist
 2nd Floor, National Medical Library Building
 Ring Road, Ansari Nagar, New Delhi
 Ph : 26589660, 26588226, Mobile : 9811090204
imsahq@ndf.vsnl.net.in, imsawhq@imsaonline.com

R.R. Thukral,
Vice President, IMSA WHQ

manifestations may be treated at home with advice of rest and adequate fluid intake. Instructions regarding danger signs must be given (as outlined above) and frequent reevaluation done. Borderline stable patient with hemorrhagic manifestations must be hospitalized and closely observed. Serial platelet count and hematocrit must be monitored daily until fever subsides. The blood pressure should be measured frequently for any sign of

Adapted from: *Guidelines for the Management of Dengue Fever/ Dengue Haemorrhagic Fever in Small Hospitals*, WHO, 1999

weight in lbs	ml/kg/day	weight in kg	ml/kg/day
< 15	100	< 7	220
16 - 25	75	7 - 11	165
26 - 40	60	12 - 18	132
41 - 88	40	19 - 40	88

Table: WHO guidelines for fluid replacement in dengue fever.

hypovolemia. Patients with hemorrhage with presence of any of the warning signs must be hospitalized immediately. Serial and frequent monitoring of blood pressure, hematocrit and urine output is essential. Intravenous isotonic crystalloids should be given to maintain adequate hydration. The volume of fluid needed is similar as in diarrhea with moderate dehydration (5-8% deficit) as recommended by WHO (Table). Some studies suggest that colloids (dextran 70%) restore the cardiac index and normalize the packed cell volume better than crystalloids. The role of platelet transfusion is not routinely recommended and should be reserved for patients with significant bleeding and severe thrombocytopenia, although the exact platelet count at which to start transfusion is debatable.

PREVENTION

Preventive strategies for dengue are limited. A live attenuated vaccine against all the 4 serotypes is still under development. An effective vaccine for public use may not be available for 5 to 10 years. Therefore, dengue prevention assumes great importance and revolves primarily around mosquito control measures such as reduction of *A. aegypti* vector populations by preventing accumulation of water in domestic locations, use of mosquito

nets, insect repellents containing diethylmethy ItoLuamide (DEET) in 30% to 35% strength for adults and 6% - 10% for children. Although the above preventive measures may be effective in the long run, they are unlikely to affect disease transmission in the near future. There is thus, an urgent need to develop improved, proactive, laboratory based surveillance systems that can provide an early warning of an impending dengue epidemic. Such surveillance results can, at the very least, after the public to take appropriate preventive measures and physicians to diagnose and properly treat dengue/DHF cases.

REFERENCES

1. **World Health Organization.** *Dengue hemorrhagic fever: Diagnosis, treatment prevention and control*, 2nd ed Geneva: WHO, 1997.
2. **Pinheiro FP, Corber SJ.** Global situation of dengue and dengue hemorrhagic fever and its emergence in the Americas. *World Health Stat Q* 1997; 50: 161-8.
3. **World Health Organization.** *Dengue and Dengue hemorrhagic fever. Prevention and control of dengue and dengue hemorrhagic fever: comprehensive guidelines.* WHO Regional publication, SEARO No. 29, 1999.
4. **Halstead SB.** Is there an inapparent dengue explosion? *Lancet* 1999; 353: 1100-1.
5. **Gubler DJ.** Dengue and dengue hemorrhagic fever. *Clin Microbiol Rev* 1998; 11: 480-496.
6. **Berry N, Chakravarti A, Gur R, Mathur MD.** *Journal of Clinical Microbiology* 1998;9:2795-2796.
7. **Bhattacharjee N, Mukherjee KK, Chakravarti SK, Mukherjee MK, De, PN, Sengupta M, Banik GB, Bhowmick P, Sinha SK, Chakroborty MS.** Dengue hemorrhagic fever outbreak in Calcutta -1990. *J. Commun Dis.* 1993; 25:10-14.
8. **Gore MM.** Need for constant monitoring of dengue infections, *Indian J Med Res* 2005 : 121(1) 9-12.
9. **Vijayakumar TS, Chandy S, Satish N, Abraham M, Abraham P, Sridharan G.** Is dengue emerging as a major public health problem? *Indian J Med Res.* 2005; 121(2):100-107
10. **Park K.** Dengue Syndrome. In *Park's Textbook of Preventive and social Medicine* 16th Ed, Jabalpur: M/s Banarsidas Bhanot 2000; 186-189.
11. **Harrington LC, Edman JD, Scott TW.** Why do female *Aedes aegypti* (Diptera: Culicidae) feed preferentially and frequently on human blood? *J. Med Entomol* 2001; 38:411-422.
12. **Gibbons RV, Vaughn DW.** Dengue: an escalating problem. *BMJ* 2002; 324: 1563-1566.
13. **Lei HY, Yeh TM, Liu HS, Lin YS, Chen SH, Liu CC.** Immunopathogenesis of dengue virus infection. *J. Biomed Sci* 2001; 8:377-388.
14. **Kurane I, Takasaki T.** Dengue fever and dengue haemorrhagic fever challenges of controlling an enemy still at large. *Rev. Med Virol* 2001; 11:301-311.
15. **Thein S, Aung MM, Shwe TN, Aye M, Zaw A, Aye K, Aye KM, Aaskov J.** Risk factors in dengue shock syndrome. *AM J Trop Med Hyg* 1997;56:566-572.
16. **Solomon T, Dung NM, Vaughn DW, Kneen R, Thao LT, Raengsakulrach B, Loan HT, Day NP, Farrar J, Myint KS, Warrell MJ, James WS, Nisalak A, White NJ** Neurological manifestations of dengue infection. *Lancet* 2000; 355:1053-1059.
17. **Gaulier C, Angibaud G, Laille M, Lacassin F.** Probable Miller Fisher Syndrome during dengue fever type 2. *Rev Neurol* 2000;156:169-171.
18. **Kao C, King C, Chao D, Wu H, Chang GJ.** Laboratory diagnosis of dengue virus infection current and future perspective in clinical diagnosis and public health. *J. Microbiol Immunol Infect* 2005;38:5-16
19. **Paula SO, Fonseca BAL.** Dengue A review of the laboratory tests a clinician must know to achieve a correct diagnosis. *Braz J Infect Dis* 2004;8:390-8

IMSACON 2008, Dubai, UAE

IMSACON- 2008 to be held IN DUBAI ON 12-13 OCTOBER 2008

This is to bring to the knowledge of prospective delegates/participants that during the time of IMSACON – 2008 in Dubai, GTEX which is considered to be one of the biggest exhibition in Dubai will be held more or less on the same dates; so the hotel booking can cause a concern for the delegates. As such it is advisable for the participants to pass the word around to other prospective delegation have hotel booking done at the as early possible.

H.K. Chopra
Secretary General, IMSA